Takeda Pharmaceutical Company Limited

TSE:4502 Lagerbericht

Marktkapitalisierung: JP¥6.5t

Takeda Pharmaceutical Management

Management Kriterienprüfungen 2/4

Takeda Pharmaceutical CEO ist Christophe Weber , ernannt in Jun 2014, hat eine Amtszeit von 10.42 Jahren. Die jährliche Gesamtvergütung beträgt ¥2.08B , bestehend aus 15.2% Gehalt und 84.8% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.05% der Aktien des Unternehmens, im Wert von ¥3.23B . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 7.1 Jahre bzw. 8.4 Jahre.

Wichtige Informationen

Christophe Weber

Geschäftsführender

JP¥2.1b

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts15.2%
Amtszeit als Geschäftsführer10.4yrs
Eigentum des Geschäftsführers0.05%
Durchschnittliche Amtszeit des Managements7.1yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder8.4yrs

Jüngste Management Updates

Recent updates

Results: Takeda Pharmaceutical Company Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Nov 04
Results: Takeda Pharmaceutical Company Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥98.00

Sep 24
Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥98.00

Why Investors Shouldn't Be Surprised By Takeda Pharmaceutical Company Limited's (TSE:4502) P/E

Sep 20
Why Investors Shouldn't Be Surprised By Takeda Pharmaceutical Company Limited's (TSE:4502) P/E

Takeda Pharmaceutical's (TSE:4502) Upcoming Dividend Will Be Larger Than Last Year's

Aug 08
Takeda Pharmaceutical's (TSE:4502) Upcoming Dividend Will Be Larger Than Last Year's

Earnings Beat: Takeda Pharmaceutical Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 02
Earnings Beat: Takeda Pharmaceutical Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥98.00

Jul 25
Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥98.00

Takeda Pharmaceutical's (TSE:4502) Upcoming Dividend Will Be Larger Than Last Year's

Jul 11
Takeda Pharmaceutical's (TSE:4502) Upcoming Dividend Will Be Larger Than Last Year's

Takeda Pharmaceutical Company Limited (TSE:4502) Yearly Results: Here's What Analysts Are Forecasting For This Year

Jun 30
Takeda Pharmaceutical Company Limited (TSE:4502) Yearly Results: Here's What Analysts Are Forecasting For This Year

Takeda Pharmaceutical (TSE:4502) Takes On Some Risk With Its Use Of Debt

Jun 11
Takeda Pharmaceutical (TSE:4502) Takes On Some Risk With Its Use Of Debt

Some Investors May Be Willing To Look Past Takeda Pharmaceutical's (TSE:4502) Soft Earnings

May 21
Some Investors May Be Willing To Look Past Takeda Pharmaceutical's (TSE:4502) Soft Earnings

Takeda Pharmaceutical Company Limited Just Recorded A 6.0% EPS Beat: Here's What Analysts Are Forecasting Next

May 12
Takeda Pharmaceutical Company Limited Just Recorded A 6.0% EPS Beat: Here's What Analysts Are Forecasting Next

Takeda Pharmaceutical (TSE:4502) Is Due To Pay A Dividend Of ¥94.00

Mar 28
Takeda Pharmaceutical (TSE:4502) Is Due To Pay A Dividend Of ¥94.00

Takeda Pharmaceutical (TSE:4502) Has Announced A Dividend Of ¥94.00

Mar 13
Takeda Pharmaceutical (TSE:4502) Has Announced A Dividend Of ¥94.00

Takeda Pharmaceutical (TSE:4502) Will Pay A Dividend Of ¥94.00

Feb 26
Takeda Pharmaceutical (TSE:4502) Will Pay A Dividend Of ¥94.00

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Christophe Weber im Vergleich zu den Einnahmen von Takeda Pharmaceutical verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 30 2024n/an/a

JP¥290b

Jun 30 2024n/an/a

JP¥150b

Mar 31 2024JP¥2bJP¥317m

JP¥144b

Dec 31 2023n/an/a

JP¥178b

Sep 30 2023n/an/a

JP¥192b

Jun 30 2023n/an/a

JP¥301b

Mar 31 2023JP¥2bJP¥295m

JP¥317b

Dec 31 2022n/an/a

JP¥275b

Sep 30 2022n/an/a

JP¥213b

Jun 30 2022n/an/a

JP¥197b

Mar 31 2022JP¥2bJP¥281m

JP¥230b

Dec 31 2021n/an/a

JP¥439b

Sep 30 2021n/an/a

JP¥473b

Jun 30 2021n/an/a

JP¥431b

Mar 31 2021JP¥2bJP¥267m

JP¥376b

Dec 31 2020n/an/a

JP¥181b

Sep 30 2020n/an/a

JP¥56b

Jun 30 2020n/an/a

JP¥120b

Mar 31 2020JP¥2bJP¥273m

JP¥44b

Dec 31 2019n/an/a

JP¥13b

Sep 30 2019n/an/a

JP¥83b

Jun 30 2019n/an/a

JP¥64b

Mar 31 2019JP¥2bJP¥269m

JP¥135b

Dec 31 2018n/an/a

JP¥110b

Sep 30 2018n/an/a

JP¥141b

Jun 30 2018n/an/a

JP¥120b

Mar 31 2018JP¥1bJP¥254m

JP¥187b

Vergütung im Vergleich zum Markt: ChristopheDie Gesamtvergütung ($USD13.50M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt JP ($USD1.38M).

Entschädigung vs. Einkommen: ChristopheDie Bezüge der Mitarbeiter sind im vergangenen Jahr um mehr als 20 % gestiegen.

Geschäftsführer

Christophe Weber (58 yo)

10.4yrs

Amtszeit

JP¥2,083,000,000

Vergütung

Mr. Christophe Weber has been the President and Chief Executive Officer of Takeda Pharmaceutical Company Limited since June 27, 2014 and April 2015 respectively and served as its Chief Operating Officer fr...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Christophe Weber
President10.4yrsJP¥2.08b0.050%
¥ 3.2b
Seigo Izumo
Chair of Management Boardno datakeine Datenkeine Daten
Milano Furuta
CFO & Directorless than a yearkeine Daten0.00083%
¥ 54.1m
Haruhiko Hirate
Member of Management Boardno datakeine Datenkeine Daten
Salvatore Alesci
Member of Management Board and Head of R&D Global Science & Biomedical Policyno datakeine Datenkeine Daten
Norimasa Takeda
Chief Accounting Officer & Corporate Controllerno datakeine Datenkeine Daten
Iwaaki Taniguchi
Senior Vice President of Corporate Finance & Controlling Department11.7yrskeine Datenkeine Daten
Gabriele Ricci
Chief Data & Technology Officer2.8yrskeine Datenkeine Daten
Christopher David O'Reilly
Global Head of Investor Relations & Global Finance4.2yrskeine Datenkeine Daten
Yoshihiro Nakagawa
Global General Counsel10.1yrskeine Datenkeine Daten
Mwana Lugogo
Chief Ethics & Compliance Officer10.1yrskeine Datenkeine Daten
Lauren Duprey
Chief Human Resources Officer3.8yrskeine Datenkeine Daten

7.1yrs

Durchschnittliche Betriebszugehörigkeit

51.5yo

Durchschnittliches Alter

Erfahrenes Management: 4502Das Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (7.1 ).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Christophe Weber
President10.4yrsJP¥2.08b0.050%
¥ 3.2b
Milano Furuta
CFO & Directorno datakeine Daten0.00083%
¥ 54.1m
Andrew S. Plump
President of Research & Development and Representative Director9.4yrsJP¥972.00m0.0087%
¥ 569.2m
John M. Maraganore
Independent External Director2.4yrsJP¥32.00mkeine Daten
Steven S. Gillis
Independent External Director5.8yrsJP¥44.00m0.00026%
¥ 17.0m
Emiko Higashi
Independent External Director8.4yrsJP¥49.00m0.00016%
¥ 10.4m
Yoshiaki Fujimori
Independent External Director8.4yrsJP¥40.00m0.00079%
¥ 51.5m
Ian T. Clark
Independent External Director5.8yrsJP¥44.00m0.000070%
¥ 4.6m
Jean-Luc Butel
Independent External Director5.4yrsJP¥38.00mkeine Daten
Michel Orsinger
Independent External Director8.4yrsJP¥46.00mkeine Daten
Masami Iijima
Independent External Chair3.4yrsJP¥43.00m0.000020%
¥ 1.3m
Koji Hatsukawa
Independent External Director8.4yrsJP¥43.00m0.00063%
¥ 41.1m

8.4yrs

Durchschnittliche Betriebszugehörigkeit

66.5yo

Durchschnittliches Alter

Erfahrener Vorstand: 4502Die Vorstandsmitglieder gelten als erfahren (8.4 Jahre durchschnittliche Amtszeit).